Clinical trial
Phase II Study of Fludarabine and Mitoxantrone, Followed by…
NCT00208975 · Emory University, Other · Terminated
Key facts
| NCT number | NCT00208975 |
|---|---|
| Title | Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab |
| Official title | Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability |
| Lead sponsor | Emory University, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF |
| Enrollment | 15 |
| Start date | Jul 1, 2002 |
| Primary completion | Dec 1, 2009 |
| Completion | Sep 1, 2011 |
| First posted | Sep 21, 2005 |
| Last update posted | Jun 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: